Antibody-drug conjugates (ADCs) are a revolutionary development in cancer treatment, combining monoclonal antibodies with highly potent cytotoxic agents for targeted therapy. This targeted delivery system enhances treatment effectiveness while minimizing systemic toxicity, positioning ADCs as a key innovation in oncology